#China #Chengdu #Sacituzumab #TROP2 #NSCLC

Insights from the OptiTROP-Lung04 Study

The recent presentation of the final overall survival (OS) analysis results from the Phase III OptiTROP-Lung04 study highlighted the significant advancement of sacituzumab tirumotecan (sac-TMT) in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, these findings have the potential to reshape therapeutic approaches for patients with epidermal growth factor receptor (EGFR)-mutant NSCLC.

In this groundbreaking study, patients receiving sac-TMT as a monotherapy showed an impressive median OS extension of 8.5 months compared to those treated with traditional platinum-based doublet chemotherapy. Specifically, the median OS was noted at 25.9 months for sac-TMT versus 17.4 months for the chemotherapy cohort. This outcome translated into a substantial 31% decrease in the risk of death, indicating a promising direction for further clinical exploration and application of this therapy.

With a median follow-up of 32.3 months, the two-year OS rate was reported at 54.1% for the sac-TMT group, contrasting with 37.2% in the chemotherapy group—a remarkable 16.9% enhancement in survival rates. This extended follow-up period underlines the durability of the survival benefits experienced by patients receiving sac-TMT, an essential consideration in the oncology field where long-term patient outcomes are paramount.

The study further examined how subsequent treatments affected outcomes. Particularly, when accounting for patients who received follow-up therapies, the adjusted median OS difference increased to 9.3 months, reiterating the therapeutic edge sac-TMT offers. Additionally, the risk of death, when analyzed through the prespecified rank-preserving structural failure time (RPSFT) model, revealed a striking 43% reduction, demonstrating the robustness of sac-TMT's efficacy even in complex treatment scenarios.

From a safety perspective, the study reported that no new safety concerns arose throughout the extended follow-up period. The majority of treatment-related adverse events were categorized as hematological issues or stomatitis, with the latter primarily manifesting as Grade 1–2 and manageable by clinical standards. Notably, instances of serious interstitial lung disease or pneumonitis were minimal, occurring significantly less frequently in the sac-TMT cohort compared to traditional chemotherapy.

Professor Wenfeng Fang of the Sun Yat-sen University Cancer Center, who presented the study findings, emphasized the importance of these results in the context of progressing disease after EGFR tyrosine kinase inhibitor (TKI) therapy. He stated that achieving extended survival remains a crucial objective, and the data collected provides compelling evidence that sac-TMT significantly enhances OS while simultaneously lowering the mortality risk for this challenging patient demographic.

Background on sac-TMT

Sac-TMT, a novel antibody-drug conjugate (ADC), targets TROP2 and represents a key therapeutic innovation developed by Sichuan Kelun-Biotech. The drug holds particular promise for advanced solid tumors, including NSCLC, due to its unique mechanism which combines both a monoclonal antibody and an innovative linker designed for optimal drug delivery and efficacy. As of the latest regulatory developments, sac-TMT has secured approval for multiple indications within China, reflecting its substantial potential in the oncology landscape.

The implications of the OptiTROP-Lung04 study underscore the evolving therapeutic options for patients with NSCLC, particularly those with EGFR mutations resistant to standard therapies. The findings from this study not only offer hope for improved patient outcomes but also represent a vital advancement in the ongoing fight against lung cancer.